International Symposium on LifeChips 2006

Drug delivery pumps today – how far have we come?
No abstract

Biography
Bill Van Antwerp was the first chemist and one of the first scientists to join Minimed in 1985, after several years successful consulting for them. The original product goal was to develop stable insulin for implantable pumps. The pumps went into clinical trials in 1992. While at Minimed, Bill was involved in developing the first FDA approved continuous glucose monitor and in pioneering continuous protein drug delivery for a variety of disease states. This work has led to successful NDA labeling of one drug and several drugs are now in late stage clinical trials. During this time, Bill developed a core group of protein analytical science and protein biophysics at Minimed. Since being acquired by Medtronic in 2001, Bill has been elected to the Bakken Society, Medtronic's highest technical achievement and has been active in corporate strategic development of biotech and drug delivery therapies. Bill has a B.S. from Rutgers University and an M.S. from SUNY. Bill serves as one of the industrial advisors to CNSI and is actively involved in using nanotechnology concepts and tools in next generation medical devices.